EUVIMEDEUVIMED entdecken
Crossref

FGFR2/3-Altered Intrahepatic Cholangiocarcinoma: A Distinct Clinicopathologic and Molecular Subtype Associated with Improved Disease-Specific Survival

Wen-Yu Hsiao, Kartik Angara, Haider A Mejbel

Modern Pathology · 2026-12 · 39 (12) · 101094

DOI: 10.1016/j.modpat.2026.101094 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2026-12. Verfasst von Wen-Yu Hsiao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Gastrointestinal and Liver Pathology, Emory University School of Medicine, Atlanta, Georgia. Die Arbeit nennt 61 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intrahepatic cholangiocarcinoma (iCCA) is an aggressive neoplasm with a poor prognosis. Fibroblast growth factor receptor (FGFR) has emerged as a therapeutic target; however, the clinicopathologic, molecular, and prognostic features of FGFR-altered iCCAs remain incompletely defined. Thus, a 5-year retrospective study of genomically profiled iCCAs using dual whole-exome and whole-transcriptome sequencing, stratified by FGFR2/3 alteration status, was performed to examine their clinicopathologic characteristics, biomarker expression, molecular profile, and prognostic significance on overall (OS), metastasis-free (MFS), progression-free (PFS), and disease-specific survival (DSS). Ninety iCCAs (25 [27.8%] FGFR2/3-altered and 65 [72.2%] FGFR2/3-wild-type) were identified. FGFR2/3-altered iCCAs encompassed FGFR2 fusions (BICC1, AHCYL1, CREB5, NOL4, NRAP, PAH, POC1B, SH3GLB1, BAIAP2L1, FKBP15, LRRFIP2, and TNS3), FGFR3::TACC3 fusion, and FGFR2 mutations (C382R and Y375C). FGFR2/3-altered iCCA patients were significantly younger (median, 61.0 vs 68.0 years; P = .014), with larger (median, 9.6 vs 6.4 cm; P = .002), well-differentiated (24.0% vs 1.5%; P 2.5 ng/mL (lower PFS), TP53 mutation (lower OS), KRAS mutation (lower OS and DSS), radiotherapy (higher OS), and surgical resection (higher OS, MFS, and DSS). FGFR2/3-altered iCCAs represent a distinct subtype associated with improved DSS, driven by inherent clinicopathologic and co-molecular characteristics rather than FGFR2/3 alteration status alone. Genomic profiling expands the molecular landscape of iCCAs, refines prognostication, and informs patient selection for targeted therapy.

Schlagwörter

Stichwörter der Autor:innen

FGFR2/3 alterationintrahepatic cholangiocarcinomamolecular landscapesurvivaltargeted therapy

Autor:innen und Institutionen

  • Department of Pathology, Gastrointestinal and Liver Pathology, Emory University School of Medicine, Atlanta, Georgia.
  • Caris Life Sciences, Irving, Texas.
  • Department of Pathology, Gastrointestinal and Liver Pathology, Emory University School of Medicine, Atlanta, Georgia; Department of Pathology, Molecular Genetics Pathology, Emory University School of Medicine, Atlanta,…

Zitieren

APA

Hsiao, W. Y., Angara, K., & Mejbel, H. A. (2026). FGFR2/3-Altered Intrahepatic Cholangiocarcinoma: A Distinct Clinicopathologic and Molecular Subtype Associated with Improved Disease-Specific Survival. Modern Pathology, 39(12), 101094. https://doi.org/10.1016/j.modpat.2026.101094

Vancouver

Hsiao WY, Angara K, Mejbel HA. FGFR2/3-Altered Intrahepatic Cholangiocarcinoma: A Distinct Clinicopathologic and Molecular Subtype Associated with Improved Disease-Specific Survival. Modern Pathology. 2026;39(12):101094. doi:10.1016/j.modpat.2026.101094

BibTeX
@article{Hsiao2026,
  author = {Hsiao, Wen-Yu and Angara, Kartik and Mejbel, Haider A},
  title = {FGFR2/3-Altered Intrahepatic Cholangiocarcinoma: A Distinct Clinicopathologic and Molecular Subtype Associated with Improved Disease-Specific Survival},
  journal = {Modern Pathology},
  year = {2026},
  volume = {39},
  number = {12},
  pages = {101094},
  doi = {10.1016/j.modpat.2026.101094}
}
Kostenlos starten →